Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
January 09, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
January 03, 2024 21:29 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
January 03, 2024 16:05 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
January 03, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report...
December 11, 2023 06:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in...
November 07, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
November 06, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
November 02, 2023 09:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
October 04, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...